Cell & Gene Therapy Commercialization: The Services Landscape in 2026

TL;DR

Cell and gene therapy commercialization is the most operationally complex vendor category in pharma services. The stack biotechs assemble for a CGT launch looks almost nothing like the one used for a conventional specialty biologic or even a rare-disease small molecule. Treatment sites must hold FACT or JACIE accreditation and clear 6-12 month activation timelines per center. Logistics require cryogenic (-130 to -196°C) or ultra-cold (-70 to -80°C) shipping with Chain of Identity tracking for autologous products. Hubs function as air-traffic control rather than refill engines, orchestrating apheresis scheduling, manufacturing slot reservation, lymphodepletion bridging, infusion logistics, and multi-year follow-up. Specialty pharmacies that participate are a curated group with cryo infrastructure and CGT-specific case management. Payer contracting is dominated by outcomes-based agreements, milestone payments, and the CMS CGT Access Model. With dozens of FDA-approved CGTs and a global gene, cell, and RNA therapy pipeline measured in thousands of programs and trials, the services opportunity is expanding faster than most pharma services segments.

Why the CGT Vendor Stack Is Categorically Different

Five structural features of CGTs drive a purpose-built services architecture:

1. One-time dosing. No refill cycle, no adherence management in the traditional sense. Post-treatment service is multi-year long-term follow-up (LTFU), not monthly fulfillment.
2. Ultra-high unit prices. Approved CGTs list from $373,000 (Luxturna) to $4.25 million (Hemgenix), creating unprecedented reimbursement and patient financial toxicity challenges.
3. Tiny patient populations. Many indications treat a few hundred to a few thousand patients per year nationally. Hub service economics invert: low volume, very high touch, per-patient fees that would be uneconomic in traditional specialty.
4. Patient-product identity. In autologous therapies (CAR-T, some next-gen gene-modified therapies), the patient’s own cells are the product. Chain of Identity (CoI) is distinct from Chain of Custody (CoC) and mix-ups are patient-safety catastrophes, not quality events.
5. Active logistics orchestration. Supply chains are circular (patient to manufacturer to patient), time-critical, and cryogenic or ultra-cold. Passive distribution is insufficient.

What’s Different vs. Traditional Specialty Biologics

Dimension	Traditional Specialty Biologic	Gene Therapy (AAV)	Autologous Cell Therapy (CAR-T)
Dosing	Chronic, monthly or quarterly	One-time infusion	One-time infusion
Unit price	$50K-$200K/year	$1M-$4.25M	$400K-$1.5M
Storage	2-8°C	-70 to -80°C	-130 to -196°C (cryogenic)
Supply chain	Linear	Linear, ultra-cold	Circular, cryogenic
Batch	Bulk	Small batch	Patient-specific (autologous)
Identity	Lot/NDC	Lot/NDC	Chain of Identity (patient-specific)
Reimbursement	Pharmacy or medical benefit	Medical benefit	Medical benefit
Site of care	Home, infusion suite, clinic	Certified infusion center	FACT-accredited IEC program
Site activation	Days-weeks for SP enrollment	Months for certified center	6-12 months per ATC
Hub primary role	Benefits verification, copay, adherence	Benefits orchestration, site activation, financial assistance	Chain of Identity, apheresis scheduling, manufacturing slot reservation, travel/lodging

Sources: Synthesized from CMS/FDA publications, FACT accreditation data, and published CGT launch case studies; dollar figures directional.

The CGT Service Stack

Breaking the typical CGT launch into discrete vendor functions shows how unconventional the stack is. Each row below is roughly a separate procurement.

Function	Vendor category	Named examples	Typical cost range (est.)
Treatment center identification & activation	CGT launch consulting, MSLs, site activation PMOs	Internal medical affairs, IQVIA, Lumanity, boutique site activation firms	$500K-$2M per center; $10-40M total
Hub orchestration	CGT-capable hub platforms	EVERSANA Gene Therapy, Cencora/Lash Group (TrakCel), McKesson InspiroGene, AssistRx Gene Therapy, Sonexus, CareMetx, ConnectiveRx, RareMed, Valeris	$5-15M year 1; PPPM $3K-$10K for ultra-rare
Specialty pharmacy (where applicable)	CGT-capable specialty pharmacies	Orsini Specialty Pharmacy, PANTHERx Rare, Accredo GeneAXS, CVS Specialty Pharmacy GCIT, OptumRx Specialty Pharmacy Frontier Therapies	Dispensing fees $500-$5K per Rx; program fees variable
Cryogenic / ultra-cold logistics	Vein-to-vein cryo carriers; ultra-cold couriers	Cryoport, World Courier, Marken, Quick Specialty Logistics	$15K-$40K per patient shipment (CAR-T); $1K-$5K (AAV)
Cold-chain packaging	Specialty containers & phase-change materials	CSafe, Cold Chain Technologies, ThermoSafe, Cryopak	Program-dependent
Payer contracting / outcomes-based agreements	Market access consultants, actuarial firms	Milliman, Avalere, Trinity Life Sciences, IQVIA, Lumanity	$1-3M for initial contract strategy
Patient finder / genotyping networks	Diagnostic labs, referral platforms	Invitae (now Labcorp), Natera, PerkinElmer Genomics, rare-disease analytics vendors	Often absorbed in manufacturer genotyping sponsorship programs
Data analytics & real-world evidence	CGT analytics, RWD platforms	IQVIA, Veeva Systems, IntegriChain, Komodo Health, ConcertAI	$500K-$3M/year
REMS management (where required)	REMS-certified hubs, software	CGT hub vendors above, REMS platform vendors	Bundled into hub fees
Long-term follow-up registry	Registry vendors, ePRO platforms	IQVIA, Syneos, Medidata, boutique registry vendors	$500K-$2M/year for 15-year LTFU

All dollar figures are estimates synthesized from public launch commentary, vendor marketing, and industry reports. Actual pricing is highly negotiated and varies by therapy complexity, patient population, and required geographies.

Treatment Center Network Management

This is the most underappreciated line item in a CGT launch. For cell therapies in particular, no patient gets treated until a center is activated, and activation is genuinely multi-stage engineering work.

FACT / JACIE Accreditation

Cellular therapy administration in the US and Europe is governed by two accreditation bodies:

• FACT (Foundation for the Accreditation of Cellular Therapy): US-centric; accredits immune effector cell (IEC) programs as well as hematopoietic stem cell transplantation. FACT maintains the accredited-institutions directory for cellular therapy programs, but commercial CAR-T delivery remains concentrated in a smaller set of activated centers.
• JACIE (Joint Accreditation Committee ISCT-EBMT): European counterpart; most commercial CAR-T and CGT programs in the EU dispense via JACIE-accredited centers.

FACT accreditation is a 12-18 month process for a site that has never dispensed a cell therapy. For a center with an existing oncology/transplant program, commercial readiness for a new CGT generally requires 6-12 months on top of accreditation: contract execution with the manufacturer, credentialing of clinicians on the specific product, training on apheresis-to-infusion workflow, integration of the manufacturer’s EMR/portal into site operations, and pharmacy and financial clearance.

June 2025 CAR-T REMS Elimination

In June 2025 the FDA eliminated REMS for approved autologous CAR-T products, concluding that product labeling could adequately communicate cytokine release syndrome and neurologic-toxicity risks. This was a landmark deregulatory event. It removed special certification requirements for hospitals and associated clinics that dispense the covered products, but commercial readiness still depends on FACT-aligned operations, manufacturer onboarding, payer contracting, and treatment-center capacity.

The competitive implications are still playing out. Hub vendors that had priced CAR-T services assuming REMS certification workflows (prescriber training, dispense verification, RMA processing) are re-pricing. Vendors that historically competed on site activation speed and outcomes tracking - functions unaffected by REMS removal - gained relative share. Gene therapies mostly remain under REMS or manufacturer-imposed limited distribution; the 2025 change was CAR-T-specific.

Cryo-Cold Chain & Vein-to-Vein Logistics

Cold-chain complexity in CGT is an order of magnitude above standard specialty. The reference architecture for autologous cell therapy looks roughly like this:

1. Apheresis at the treatment center collects the patient’s T-cells (or other starting material).
2. Cryopreservation & vein-to-manufacturer shipping moves the starting material to the manufacturing site in liquid-nitrogen dry-shipping dewars (typically -150°C or colder in the vapor phase of LN2).
3. Manufacturing takes place over 2-4 weeks, during which a manufacturing slot must remain reserved and patient status tracked.
4. Return shipping to the treatment center at cryogenic temperatures, with Chain of Identity verification at receipt.
5. Thaw, infusion, and post-treatment monitoring at the certified treatment center.

Median vein-to-vein time across commercial autologous CAR-Ts is approximately 31 days. Every day of delay is clinically meaningful for aggressive oncology indications.

Specialty Cryo Carriers

A small number of carriers hold the physical infrastructure, custody protocols, and regulatory credentials to move commercial CAR-T and related autologous products. The dominant names in 2026:

• Cryoport - market leader for commercial CAR-T cryogenic shipping; proprietary SmartPak condition-monitoring dewars; integrated with all commercial CAR-T manufacturers’ supply chains.
• World Courier (part of Cencora) - strong clinical-trial heritage; expanding commercial CAR-T footprint via Cencora CGT orchestration.
• Marken (UPS Healthcare) - clinical-stage focus with commercial expansion, part of UPS’s broader healthcare logistics integration.
• Quick Specialty Logistics (part of Kuehne+Nagel) - time-critical biologic and CGT logistics.

For AAV gene therapies, ultra-cold storage (-70 to -80°C) is served by a broader set of vendors, but the small-batch, patient-specific nature of many gene therapies still requires active logistics orchestration rather than passive distribution. Packaging vendors - CSafe, Cold Chain Technologies, ThermoSafe, and Cryopak - provide qualified shippers, phase-change materials, and integration with temperature-monitoring platforms.

Hub Services for CGT: Air Traffic Control, Not Call Center

Conventional specialty hubs are optimized for benefits verification, prior authorization, copay enrollment, and refill management at volume. CGT hubs look entirely different. They function as orchestration platforms coordinating:

• Benefits verification under the medical benefit (not pharmacy benefit)
• Financial counseling for patients facing five- and six-figure out-of-pocket exposure
• Genetic testing coordination and results tracking (for indication-qualifying variants)
• Apheresis scheduling at certified collection centers
• Manufacturing slot reservation with the therapy manufacturer
• Lymphodepleting chemotherapy bridging between community oncologist and treatment center
• Infusion scheduling at the FACT-accredited treatment center
• Travel and lodging logistics (patients often travel interstate to distant centers)
• Multi-year outcomes tracking and LTFU data collection for FDA post-marketing commitments

Named CGT Hub Platforms in 2026

• EVERSANA Gene Therapy - part of EVERSANA COMPLETE Commercialization; integrates hub, payer engagement, and commercial analytics.
• Cencora / Lash Group - uses TrakCel as the Chain of Identity and orchestration engine; benefits from Cencora’s distribution data footprint.
• McKesson InspiroGene - purpose-built CGT orchestration platform; CoverMyMeds connectivity for coverage workflows.
• AssistRx Gene Therapy - leverages AssistRx’s EHR-native enrollment heritage; rare-disease and CGT-specific workflows.
• Sonexus (Cardinal Health) - ConnectSource platform extended to CGT programs; speech analytics and AI applied to ultra-low-volume case management.
• CareMetx - Digital Hub + OutcomeRx value-based contracting workflows.
• ConnectiveRx - hub services plus Careform noncommercial pharmacy useful for bridging programs.
• RareMed Solutions - rare-disease and ultra-orphan dedicated hub, relevant to CGT indications with tiny populations.
• Valeris (PharmaCord + Mercalis) - post-merger independent patient access platform supporting CGT programs.

Specialty Pharmacies Equipped for CGT

Most specialty pharmacies are categorically unequipped for CGT: no cryo storage, no Chain of Identity systems, no CGT-specific case management staffing. A small group has invested to participate.

SP	Key positioning
Orsini Specialty Pharmacy	Dispensed more distinct cell and gene therapies than any other SP in the industry; integrated hub + SP + 3PL model; rare-disease heritage
Accredo (Cigna/Evernorth)	GeneAXS gene therapy program; scale advantages via Express Scripts parent
CVS Specialty Pharmacy	Gene & Cell Innovation Therapy (GCIT) program; leverages Coram infusion and specialty footprint
PANTHERx Rare	Rare-disease focused; CGT capabilities via rare-disease case management depth
OptumRx Specialty Pharmacy Frontier Therapies	UnitedHealth-aligned CGT access programs; emphasis on medical-benefit integration

Manufacturer CGT programs are almost always limited-distribution by design; the LDD pharmacy network typically contains 3-8 SPs across the first launch year, often expanding modestly after commercial uptake.

Payer Contracting: Outcomes-Based and Milestone Payments

Traditional rebate-and-net-price contracting breaks down at $2M-$4M per patient. Manufacturers, payers, and CMS have built an entirely new contracting toolkit for CGTs.

Key Contracting Models

• Outcomes-based agreements (OBAs): Novartis pioneered this with Kymriah’s pay-for-performance - no payment if no complete response by day 30. Since then, most commercial CGT contracts include some form of outcomes trigger (response, durability, survival).
• Milestone-based payments: The $4.25M price of Hemgenix, for example, is often contracted over multi-year milestones tied to Factor IX activity and bleeding rate outcomes.
• Annuities / installment agreements: Some commercial payers amortize single-dose prices over 3-5 years, resolving the cash-flow mismatch of one-time dosing against multi-year benefit.
• Warranty structures: Bluebird bio’s lovo-cel (Lyfgenia) launched with a commercial warranty tied to hemoglobin response.

CMS CGT Access Model

The CMS CGT Access Model (CGTAM) is a multi-state Medicaid program creating aggregated outcomes-based contracts for sickle cell CGTs (Casgevy and Lyfgenia). As of early 2026, 34 state Medicaid programs are participating. CGTAM directly addresses the single largest access bottleneck for CGTs: state Medicaid programs that cannot absorb the cash-flow shock of one-time, multi-million-dollar payments for thousands of eligible patients.

MS-DRG 018 Gap

Medicare currently reimburses roughly $247,000 for inpatient CAR-T administration under MS-DRG 018, while the drug alone costs $400,000+. The New Technology Add-on Payment (NTAP) covers 65% of excess costs, still leaving hospitals with meaningful financial exposure. The gap is unresolved as of 2026 and remains a structural access barrier for CAR-T at smaller health systems.

Vendors in This Stack

Most CGT payer-contracting work is split between a small number of specialist consultancies and internal manufacturer market access teams:

• Milliman - actuarial modeling for OBAs, milestone contracts, annuity structures
• Avalere Health - CMS policy analysis, state Medicaid engagement, CGTAM advisory
• Trinity Life Sciences - payer engagement and CGT commercial strategy
• IQVIA - real-world data and commercial analytics underpinning OBAs
• Lumanity - HEOR, payer value dossiers, evidence strategy for CGT

Patient Identification & Genotyping

Because CGT indications often depend on specific genotypes or rare disease subtypes, patient identification is its own services function. For sickle cell CGTs, Casgevy enrollment requires documented hemoglobin genotype and prior vaso-occlusive crisis history. For Elevidys (DMD), genetic confirmation of DMD mutation and age-eligibility at dosing is required. For Zolgensma (SMA), newborn screening and SMN1 genotype drive enrollment.

Patient finder vendor activity typically includes:

• Sponsored genotyping programs (Invitae/Labcorp, Natera, PerkinElmer) funded by the manufacturer and free to patients/prescribers
• Targeted analytics across claims and EMR data to identify candidate patients at community providers
• Referral orchestration to centralize candidate patients at treatment centers
• KOL and MSL-driven case finding, particularly for ultra-rare indications with <500 eligible US patients/year

These workflows overlap with the CGT hub, which typically owns the genotyping-to-enrollment-to-site-activation handoffs.

CGT Launch Case Studies

CAR-T (Kymriah, Yescarta)

The first two commercial CAR-T products established the template. Both launched under REMS with certified ATC networks; Kymriah’s day-30 outcomes-based pricing established the commercial norm. Early manufacturing cycles ran longer than today’s 31-day median, and hub orchestration matured alongside manufacturing yield improvements. The June 2025 REMS elimination has since unwound many of the original workflows.

Gene therapy: Zolgensma (SMA)

Novartis’s launch established the template for ultra-high-priced one-time gene therapies:

• $2.1M list price at launch (2019); now ~$2.25M
• Newborn screening-driven patient identification across all 50 states
• Outcomes-based and annuity contract options offered to payers
• Limited-distribution channel through a small number of pediatric neuromuscular centers

Gene therapy: Elevidys (DMD)

Sarepta’s launch in 2023 showed how CGT commercialization looks when the patient population is larger (~10,000-20,000 eligible US DMD patients) but administration capacity is limited by site specialization:

• Concentrated prescribing at pediatric neuromuscular centers
• Significant payer friction over ambulatory/non-ambulatory label dynamics
• Long-term follow-up registry commitments as part of accelerated approval

Gene therapy: Casgevy (sickle cell, beta-thalassemia)

Vertex and CRISPR Therapeutics launched the first CRISPR-edited therapy in late 2023. Commercialization highlights:

• ~$2.2M price; Lyfgenia priced at ~$3.1M for comparable sickle cell indication
• CMS CGTAM central to state Medicaid access for the large sickle cell population
• Apheresis, edited-cell manufacturing, and myeloablative conditioning each require 1-2 months of coordinated execution per patient
• FACT-accredited treatment center expansion became a gating factor; Vertex actively partnered with centers to accelerate activation

Gene therapy: Hemgenix (hemophilia B)

CSL Behring’s Hemgenix is, at $3.5M originally and $4.25M by 2026 price adjustments, among the highest-priced approved therapies. It demonstrated:

• Hub-orchestrated benefits investigation under medical benefit dominates the access workflow
• Outcomes-based contracts tied to Factor IX activity and bleeding events
• Small specialty pharmacy network: Orsini, Accredo GeneAXS, and select others
• Very small eligible population (estimated ~6,500 US hemophilia B patients with severe disease)

Economics of the CGT Launch Stack

For a typical autologous cell therapy or gene therapy launch, a first-year commercialization spend of $10-50M+ across the vendor stack is a reasonable estimate, compared to $3-10M for a typical specialty biologic. The rough composition:

Category	Est. year-1 spend (directional)
Hub orchestration platform	$5-15M
Treatment center activation (20-50 centers at $500K-$2M)	$10-40M (often partially sponsored)
Cryo / ultra-cold logistics	$3-10M, variable with volume
Specialty pharmacy program fees	$500K-$3M
Market access / payer contracting	$1-3M
Patient identification / genotyping sponsorship	$2-8M
Data analytics & RWE	$500K-$3M
Long-term follow-up registry (multi-year amortized)	$500K-$2M/year

Figures are estimates synthesized from published CGT launch commentary and industry reports. Manufacturers with existing platform infrastructure (CAR-T franchises, for example) carry materially lower incremental stack cost per new indication.

For context, Rx Almanac’s hub services market analysis benchmarks cell/gene therapy hub programs at $5-15M+ annually - consistent with the hub line in the table above but excluding site activation, logistics, and market access contracting.

Market Dynamics 2026: Pipeline, Capacity, and IRA

Pipeline and Approvals

• Dozens of FDA-approved cellular and gene therapy products, with the FDA product list continuing to expand
• Global gene, cell, and RNA therapy development pipeline measured in thousands of programs and trials
• Multiple market forecasts point to rapid CGT growth through 2030, though estimates vary widely by scope and methodology

The growth forecasts should be treated with skepticism - historical pipeline conversion rates for gene therapies run 10-15%. Even conservative projections, however, point to substantial expansion of CGT services demand.

Treatment Center Capacity

Commercial CAR-T dosing capacity is heavily concentrated at a relatively small number of high-volume academic medical centers. For ultra-rare gene therapies, capacity is further concentrated at 5-20 centers of excellence per indication. Site activation is a durable bottleneck: even post-REMS, adding a new commercial center takes 6-12 months of manufacturer investment per site.

IRA Implications

The Inflation Reduction Act’s Medicare Drug Price Negotiation clock treats small-molecule and biologic/biosimilar products differently (9 vs. 13 years from approval before eligibility for negotiation). For gene therapies regulated as biologics, the 13-year clock applies. For cell therapies, classification nuances persist. IRA negotiation eligibility has not yet reached CGTs given the approval dates of the current portfolio, but is a rising strategic consideration for pricing and lifecycle decisions across the next decade.

In-Vivo vs. Ex-Vivo Shift

The most consequential structural trend is the pipeline shift from autologous ex-vivo therapies (patient-derived, cryogenic, circular supply chain) toward:

• Allogeneic “off-the-shelf” cell therapies - bulk manufactured, inventoried, linear distribution. If successful, these commoditize much of the current CAR-T logistics stack.
• In-vivo gene editing - therapies delivered directly to the patient without ex-vivo manipulation. These simplify Chain of Identity requirements but still require ultra-cold logistics and specialized administration sites.

If allogeneic and in-vivo approaches gain meaningful share, the specialized cryogenic logistics stack (Cryoport, World Courier) and the Chain of Identity layer within hubs (TrakCel, InspiroGene) face commoditization pressure over the late 2020s.

Decentralized Manufacturing

Point-of-care or regional manufacturing models are in early pilots. If viable at scale, they compress the logistics layer but increase in-center GMP, QA/QC, and regulatory compliance requirements.

Outlook: Where the Services Stack Is Heading

1. Hub repricing post-REMS. CAR-T hub fees are under pressure as REMS-associated workflows exit. Gene therapy hubs, often still under REMS or manufacturer-imposed LDD, are insulated for now.
2. SP consolidation in CGT. Expect continued concentration of CGT dispensing at 5-10 SPs with Chain of Identity and cryo capabilities. New entrants will struggle absent a differentiated rare-disease heritage.
3. Outcomes-based contracting becomes standard. Not optional for launches at >$1M list price; infrastructure investments in RWE and registry data are a launch prerequisite.
4. CMS CGTAM expansion. State participation expected to grow beyond 34 as the model demonstrates sustainability; extension beyond sickle cell CGTs is plausible.
5. Allogeneic / in-vivo pipeline maturation. If first allogeneic CAR-T or in-vivo CRISPR commercial launches succeed in the late 2020s, the services stack simplifies materially and vendor pricing power shifts away from specialist cryo logistics toward CGT-capable hub, SP, and site activation players.
6. Biotech buyer behavior. Small biotechs launching a single CGT increasingly prefer integrated commercialization partners (EVERSANA COMPLETE, Cencora CGT orchestration, McKesson InspiroGene) over assembling a point-solution stack. Integrated offerings are growing faster than individual components in the stack.

Cross-References

• Hub Services Market Analysis - CGT hub benchmarking lives inside the broader hub services analysis
• Top Specialty Pharmacies for Pharma Manufacturers - SP selection criteria applicable to CGT-capable pharmacies
• Big Three PBM Specialty Pharmacies - scale context for Accredo GeneAXS, CVS GCIT, OptumRx Frontier
• Rare Disease Launch Vendor Playbook - related playbook for ultra-rare small molecules and biologics; CGT is a distinct discipline
• Pharma Services Market Sizing - total market context for CGT services as a growth segment
• Market Access Consulting - landscape for the payer contracting and outcomes-based agreement vendors named above

---

Analysis compiled April 2026. Dollar figures for launch stack components, site activation costs, hub fees, and outcomes-based contract economics are directional estimates synthesized from public sources including company disclosures, industry analyst reports, and CGT launch case studies. They should be treated as planning-grade rather than definitive. Specific contract values are generally confidential; publicly disclosed CGT pricing reflects list, not net.